Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zogenix Inc
(NQ:
ZGNX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 4, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zogenix Inc
< Previous
1
2
Next >
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
March 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Merger Arbitrage Mondays - Healthcare Trust Of America To Combine With Healthcare Realty Trust
March 07, 2022
Merger activity increased last week with six new deals announced and six deals completed. Three of the six new deals announced were potential deals in the works. Healthcare Trust...
Via
Benzinga
Recap: Zogenix Q4 Earnings
February 28, 2022
Zogenix (NASDAQ:ZGNX) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...
Via
Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles 150 Points; Yumanity Therapeutics Shares Plunge
January 19, 2022
Toward the end of trading Wednesday, the Dow traded down 0.45% to 35,210.04 while the NASDAQ fell 0.28% to 14,466.47. The S&P also fell, dropping, 0.29% to 4,563.94. The U.S....
Via
Benzinga
SBEV Stock: The Ralph’s Grocery Deal Making Waves for Splash Beverage Group Today
January 19, 2022
Splash Beverage (SBEV) stock is soaring higher on Wednesday after the company revealed a new deal bringing its drinks to additional stores.
Via
InvestorPlace
52 Biggest Movers From Yesterday
January 20, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 19, 2022
Gainers Zogenix (NASDAQ:ZGNX) shares moved upwards by 67.2% to $26.15 during Wednesday's regular session. As of 12:30 EST, Zogenix's stock is trading at a volume...
Via
Benzinga
Mid-Day Market Update: US Stocks Turn Negative; Zogenix Shares Spike Higher
January 19, 2022
Midway through trading Wednesday, the Dow traded down 0.13% to 35,321.51 while the NASDAQ fell 0.53% to 14,430.41. The S&P also fell, dropping, 0.19% to 4,568.33. The U.S. has...
Via
Benzinga
Zogenix (ZGNX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Zogenix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ZGNX
January 19, 2022
From
Halper Sadeh LLP
Via
Business Wire
GENI Stock: The Analyst Call Sending Genius Sports Shares Surging Today
January 19, 2022
Genius Sports (GENI) stock is on the rise Wednesday after an analyst initiated coverage of the sports data and tech company.
Via
InvestorPlace
35 Stocks Moving In Wednesday's Mid-Day Session
January 19, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion. Splash Beverage Group,...
Via
Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
January 19, 2022
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal.
Via
InvestorPlace
Mid-Morning Market Update: Markets Rise; Bank of America Posts Upbeat Profit
January 19, 2022
Following the market opening Wednesday, the Dow traded up 0.12% to 35,411.14 while the NASDAQ rose 0.90% to 14,638.13. The S&P also rose, gaining, 0.44% to 4,597.47. The U.S....
Via
Benzinga
Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest
January 19, 2022
The deal includes a CVS tied to Fintepla's next potential approval.
Via
Investor's Business Daily
Why Zogenix Shares Are Soaring Today
January 19, 2022
Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 19, 2022
Gainers Zogenix (NASDAQ:ZGNX) stock rose 68.2% to $26.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.4 billion. Lucid...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 19, 2022
Good morning, investor! We're diving right into trading today with a look at the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
January 19, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares rose 56.1% to $24.41 in pre-market trading after UCB announced plans to acquire the company. Fresh Vine Wine, Inc. (NYSE: VINE) rose...
Via
Benzinga
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
January 19, 2022
Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion,...
Via
Benzinga
Why Are Zogenix's Shares Gaining Today?
December 01, 2021
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: ZGNX) supplemental marketing application seeking approval for Fintepla (fenfluramine) in...
Via
Benzinga
Exposures
Product Safety
61 Biggest Movers From Yesterday
December 02, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Recap: Zogenix Q3 Earnings
November 04, 2021
Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Zogenix...
Via
Benzinga
Zogenix Earnings Preview
November 03, 2021
Zogenix (NASDAQ:ZGNX) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
December 01, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.